Kevin Strange, Ph.D.
Co-founder, MSI-1436 Co-inventor, CEO
Dr. Strange is co-inventor of the MSI-1436 technology and president of the MDI Biological Laboratory. Prior to becoming president of the MDI Biological Laboratory in July 2009, he was an associate professor at Harvard Medical School and the John Parker Professor at Vanderbilt School of Medicine. He has been funded by the National Institutes of Health (NIH) since 1986 and has raised over $40 million in competitive federal and private research funding throughout the course of his career. Upon assuming the leadership of the MDI Biological Laboratory, Dr. Strange focused his research and development efforts on regenerative medicine. Three years after establishing this new research focus, the institution was recognized by the NIH as a Center of Biomedical Research Excellence in this field. Novo Biosciences was highlighted as a success story of this program in the 2017 budget request presented to Congress by the National Institute of General Medical Sciences.
Voot Yin, Ph.D.
Co-founder, MSI-1436 Co-inventor, Chief Scientific Officer
Dr. Yin is co-inventor of the MSI-1436 technology and an assistant professor at the MDI Biological Laboratory. He developed the screening platform that led to the discovery of MSI-1436. Dr. Yin is a recipient of NIH and Department of Defense funding and is a Young Investigator of the American Heart Association. He has extensive expertise in heart, muscle and limb tissue regenerative biology.
Michael A. Zasloff, M.D., Ph.D.
Senior Research Scientist, MSI-1436 Co-inventor
Dr. Zasloff discovered MSI-1436 and has extensive expertise in its biological properties and chemistry. He is co-inventor of the MSI-1436 regeneration application and founder of Magainin Pharmaceuticals. Dr. Zasloff has been awarded 55 U.S. and international patents. Through his clinical work and commercial ventures, he has gained extensive experience with clinical trials, the FDA approval process and investment fundraising.